Pay in 4 interest-free payments of $6.55 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
10.1038/304368a0 48
Cagrilintide, the second generation (2020s) Novo Nordisk took the Pramlintide concept and applied the same half-life extension strategy that they used with Semaglutide: Kept the proline substitutions (anti-amyloid) Added a C20 fatty diacid via a -Glu linker to a lysine residue, albumin binding Additionally stabilized the N- and C-terminal positions Result: Cagrilintide with a half-life of 6.6 days (vs 50 minutes for Pramlintide)
Ford for cell culture maintenance
Data availability The data of molecular traits used to proxy GLP-1R expression were available via deCODE genetics website ( the eQTL Gen website ( the GoDMC website ( the MetaBrain website ( and the Genotype-Tissue Expression (GTEx) Portal website ( The summary statistics of ovarian cancer for GWAS meta-analyses used in this study are deposited in the IEU OpenGWAS database (GWAS IDs ieu-a-1120 and ieu-b-4963) and FinnGen r12 defined as II Neoplasms, from cancer register (ICD-O-3) ( The GWAS summary statistics for the ovarian cancer subtypes are available at with their GWAS IDs listed in the Supplementary Data
